State of the art: Using natriuretic peptide levels in clinical practice

[1]  V. Hasselblad,et al.  Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). , 2007, The American journal of cardiology.

[2]  J. Cleland,et al.  Prognosis in heart failure with a normal ejection fraction. , 2007, The New England journal of medicine.

[3]  Nancy M Albert,et al.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.

[4]  D. J. Veldhuisen,et al.  Anaemia and renal dysfunction are independently associated with BNP and NT‐proBNP levels in patients with heart failure , 2007, European journal of heart failure.

[5]  P. Poole‐Wilson,et al.  Prognostic importance of plasma NT‐pro BNP in chronic heart failure in patients treated with a β‐blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial , 2007, European journal of heart failure.

[6]  Karen A. Hartman,et al.  Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure: The Importance of Change Over Time , 2007, Circulation.

[7]  J. Daubert,et al.  Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. , 2006, European heart journal.

[8]  J. Januzzi,et al.  N-Terminal Pro–B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study , 2007, Circulation.

[9]  C. Phillips,et al.  Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.

[10]  A. Cohen-Solal,et al.  Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. , 2007, JAMA.

[11]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[12]  D. Talmor,et al.  Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. , 2007, Chest.

[13]  R. Rodeheffer,et al.  Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. , 2007, Journal of the American College of Cardiology.

[14]  Horng H Chen,et al.  Heart failure: a state of brain natriuretic peptide deficiency or resistance or both! , 2007, Journal of the American College of Cardiology.

[15]  Y. Pinto,et al.  Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. , 2007, Archives of internal medicine.

[16]  M. Guglin,et al.  Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.

[17]  D. Phelan,et al.  The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. , 2007, Journal of cardiac failure.

[18]  Alan H B Wu,et al.  Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. , 2006, American heart journal.

[19]  A. Rigby,et al.  The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation. , 2006, European heart journal.

[20]  L. Brochard,et al.  B-type natriuretic peptide and weaning from mechanical ventilation , 2006, Intensive Care Medicine.

[21]  C. Frampton,et al.  NTproBNP‐guided drug treatment for chronic heart failure: design and methods in the “BATTLESCARRED” trial , 2006, European journal of heart failure.

[22]  Y. Pinto,et al.  Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. , 2006, The American journal of cardiology.

[23]  A. Maisel,et al.  B-type natriuretic peptide: time to incorporate natriuretic peptides in our practice , 2006, Journal of cardiovascular medicine.

[24]  C. Schindler,et al.  Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. , 2006, Archives of internal medicine.

[25]  C. Schindler,et al.  Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease: Am Heart J 2006;151:471–7 , 2006 .

[26]  J. Hollander,et al.  Gray zone BNP levels in heart failure patients in the emergency department: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. , 2006, American heart journal.

[27]  Alan S Maisel,et al.  How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. , 2006, American heart journal.

[28]  A. Jaffe,et al.  Brain natriuretic peptide levels in constrictive pericarditis and restrictive cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[29]  Y. Kihara,et al.  B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. , 2006, Journal of the American College of Cardiology.

[30]  M. Givertz,et al.  B-type natriuretic peptide and the stressed heart. , 2006, Journal of the American College of Cardiology.

[31]  C. Schindler,et al.  Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. , 2006, American heart journal.

[32]  G. Fonarow,et al.  B-type natriuretic peptide levels in obese patients with advanced heart failure. , 2006, Journal of the American College of Cardiology.

[33]  G. Fonarow.  How well are chronic heart failure patients being managed? , 2006, Reviews in cardiovascular medicine.

[34]  F. Fouad-Tarazi,et al.  Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study. , 2005, American heart journal.

[35]  T. Lim,et al.  B-type natriuretic peptide: Issues for the intensivist and pulmonologist , 2005, Critical care medicine.

[36]  D. Arab,et al.  The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[37]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[38]  E. Shapiro,et al.  Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit , 2005 .

[39]  M. Quiñones,et al.  Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure. , 2005, Journal of the American College of Cardiology.

[40]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[41]  G. Filippatos,et al.  [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. , 2005, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[42]  R. Starling,et al.  B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. , 2005, American heart journal.

[43]  K. Dickstein,et al.  [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. , 2005, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[44]  J. Bartunek,et al.  Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[45]  J. V. D. van den Ouweland,et al.  High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. , 2004, Clinical chemistry.

[46]  J. Hollander,et al.  Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. , 2004, Journal of the American College of Cardiology.

[47]  R. Pino,et al.  Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock* , 2004, Critical care medicine.

[48]  K. Bailey,et al.  Plasma Brain Natriuretic Peptide to Detect Preclinical Ventricular Systolic or Diastolic Dysfunction: A Community-Based Study , 2004, Circulation.

[49]  M. Quiñones,et al.  Optimal Noninvasive Assessment of Left Ventricular Filling Pressures: A Comparison of Tissue Doppler Echocardiography and B-Type Natriuretic Peptide in Patients With Pulmonary Artery Catheters , 2004, Circulation.

[50]  R. Kazanegra,et al.  Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. , 2004, Journal of the American College of Cardiology.

[51]  E. Frohlich,et al.  Obesity and suppressed B-type natriuretic peptide levels in heart failure. , 2004, Journal of the American College of Cardiology.

[52]  P. Shekelle,et al.  Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. , 2004, Journal of the American College of Cardiology.

[53]  M. Vogeser,et al.  Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[54]  J. Chiche,et al.  Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis , 2004, Critical care medicine.

[55]  M. Pfisterer,et al.  Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. , 2004, The New England journal of medicine.

[56]  Daniel Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death. , 2004, The New England journal of medicine.

[57]  D. Levy,et al.  Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.

[58]  P. McCullough,et al.  B-Type Natriuretic Peptide and Renal Disease , 2003, Heart Failure Reviews.

[59]  T. McDonagh,et al.  NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. , 2003, European journal of heart failure.

[60]  G. Fonarow,et al.  The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. , 2003, Reviews in cardiovascular medicine.

[61]  M. Nieminen,et al.  Clinical applications of B-type natriuretic peptide (BNP) testing. , 2003, European heart journal.

[62]  C. Frampton,et al.  Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. , 2003, Journal of the American College of Cardiology.

[63]  Richard Kamin,et al.  Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. , 2003, Journal of the American College of Cardiology.

[64]  S. Goldhaber,et al.  Prognostic Role of Brain Natriuretic Peptide in Acute Pulmonary Embolism , 2003, Circulation.

[65]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[66]  J. Hollander,et al.  Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. , 2003, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[67]  J. Hollander,et al.  B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[68]  Stephen J. Huang,et al.  Increased B-type Natriuretic Peptide (BNP) Level is a Strong Predictor for Cardiac Dysfunction in Intensive Care Unit Patients , 2003, Anaesthesia and intensive care.

[69]  Douglas W Mahoney,et al.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.

[70]  T. McDonagh,et al.  Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. , 2003, Journal of the American College of Cardiology.

[71]  C. Zanker,et al.  Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. , 2002, Journal of the American College of Cardiology.

[72]  D. Levy,et al.  Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. , 2002, JAMA.

[73]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[74]  D. Levy,et al.  Impact of age and sex on plasma natriuretic peptide levels in healthy adults. , 2002, The American journal of cardiology.

[75]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[76]  K. Nakao,et al.  B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. , 2002, The American journal of medicine.

[77]  L. Morrison,et al.  Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. , 2002, Journal of the American College of Cardiology.

[78]  M. Tamaki,et al.  Molecular forms of human brain natriuretic peptide in plasma. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[79]  N. Arakawa,et al.  Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population , 2002, Heart.

[80]  L. Morrison,et al.  Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea ☆ , 2002 .

[81]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[82]  M. Kinoshita,et al.  Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[83]  P. Krishnaswamy,et al.  A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. , 2001, Journal of cardiac failure.

[84]  L. Lenert,et al.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.

[85]  L. Lenert,et al.  Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. , 2001, Journal of the American College of Cardiology.

[86]  K. Kangawa,et al.  Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.

[87]  H. Hense,et al.  Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population , 2000, Journal of hypertension.

[88]  L. Lenert,et al.  Utility of B-natriuretic peptide (BNP) in the diagnosis of congestive heart in an urgent care setting , 2000 .

[89]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[90]  M. Domanski,et al.  The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. , 2000, Journal of the American College of Cardiology.

[91]  M. Bando,et al.  Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. , 1999, Respiratory medicine.

[92]  R. Doughty,et al.  Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 1999, Circulation.

[93]  R. Sarzani,et al.  The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. , 1998, Journal of nephrology.

[94]  M. Kinoshita,et al.  Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. , 1998, American heart journal.

[95]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[96]  S. Kuribayashi,et al.  Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. , 1998, Journal of the American College of Cardiology.

[97]  P. Poole‐Wilson,et al.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care , 1997, The Lancet.

[98]  H. Krumholz,et al.  Quality of care for elderly patients hospitalized with heart failure. , 1997, Archives of internal medicine.

[99]  Hugh Tunstall-Pedoe,et al.  Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population , 1997, The Lancet.

[100]  P. Dessı̀-Fulgheri,et al.  Expression of natriuretic peptide receptors in human adipose and other tissues , 1996, Journal of endocrinological investigation.

[101]  A. Richards,et al.  The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. , 1995, Biochemical and biophysical research communications.

[102]  K. Nakao,et al.  Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. , 1995, The Journal of clinical investigation.

[103]  S. Yusuf,et al.  Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction , 1995 .

[104]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[105]  A. Richards,et al.  Plasma brain natriuretic peptide in assessment of acute dyspnoea , 1994, The Lancet.

[106]  Michihisa Jougasaki,et al.  Different Secretion Patterns of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Patients With Congestive Heart Failure , 1993, Circulation.

[107]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[108]  K. Inouye,et al.  Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. , 1991, The Journal of clinical investigation.

[109]  N. Minamino,et al.  Brain natriuretic peptide-32: N-terminal six amino acid extended form of brain natriuretic peptide identified in porcine brain. , 1988, Biochemical and biophysical research communications.